Amgen's drug combination extends survival in a lung cancer trial
Amgen says its drug Imdelltra combined with AstraZeneca's Imfinzi cut the risk of death by 58% in a late-stage trial in extensive-stage small cell lung cancer. Nearly 80% of patients were alive at one year, against 53% on Imfinzi alone.
Left 0 · Centre-left 2 · Centre 2 · Centre-right 0 · Right 0
Sources by leanFollow the moneyMore coverage
How each side framed it
Left-leaning outlets
Left-rated outlets headline it: “Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer” (Bloomberg); “Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer” (CNBC).
Centre outlets
Centre-rated outlets headline it: “Amgen drug combined with immunotherapy extends survival in lung cancer trial” (Reuters); “IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER – Company Announcement - FT.com” (Financial Times).
Right-leaning outlets
No right-rated outlet in our sample covered it.
Sources by lean
Balanced: the same number of articles from the left, the centre and the right (up to 3 each). The bar above still counts every rated outlet we found. Bias and factual ratings come from Media Bias/Fact Check. How we balance · All ratings.
Left 2
- CNBC
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer - Bloomberg
Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer (paywalled or blocks bots)
Centre 2
Right 0
No right coverage found — blindspot
Showing 2 from left and centre of 4 rated outlets (L 2 / C 2 / R 0). Capped at 2 because that is all we found on the thinnest side. More coverage
Follow the money
Not yet researched. We haven't yet looked at who gains or loses financially from this story, or who funds the main voices on each side. When we do, we check company filings, the Electoral Commission donations register, lobbying registers, annual reports, InfluenceMap and OpenSecrets, and we apply the same checks to every side. How we follow the money.
Who owns or funds the outlets covering this story (4 outlets)
| Outlet | Lean | Ownership & funding (MBFC) |
|---|---|---|
| Bloomberg | Centre-left | Michael R. Bloomberg is the founder and majority owner of Bloomberg LP (The parent company of Bloomberg News). According to Investopedia, Bloomberg Terminal (remote software used to access financial information) is the most expensive among financial data providers. source |
| CNBC | Centre-left | CNBC is owned by NBC Universal, which Comcast owns. Comcast’s Chairman and Chief Executive Officer (CEO) is Brian L. Roberts, founded by his father, Ralph J. source |
| Financial Times | Centre | The Financial Times is owned by The Nikkei, a Japanese news and financial information company that publishes the leading financial paper, The Nikkei. The FT generates revenue through subscriptions, a hard paywall, and advertising..push({}); source |
| Reuters | Centre | In April 2008, the British company Reuters Group was acquired by Thomson Corporation and formed Thomson Reuters. source |